The latest: Internet-based auto financier Yixin Group Ltd. (2858.HK) announced Monday that its revenue jumped 73.2% year-on-year to 2.45 billion yuan ($358 million) in the first half of the year, as it returned to the black with a net profit of 124 million yuan.

Looking up: The company logged 266,000 auto financing transactions in the first half of the year, up 17% year-on-year. The value of those transactions jumped by an even larger 37% to 25 billion yuan, even as demand for vehicles shrank due to weak spending tied to China’s strict pandemic control measures.

Take Note: The group’s new vehicle financing transactions fell 24% in the first half, while the amount financed from those transactions fell 16%, mainly due to the pandemic-related supply chain disruptions and a pivot to stronger focus on the used vehicle financing business.

Digging Deeper: Yixin is a leading online auto finance trading platform in China, with internet giant Tencent (0700.HK) holding a majority 53.97% stake. The company was originally a direct provider of loans for auto buying and leasing. But it turned to intermediary services facilitating similar loans between banks and consumers after a regulatory clampdown on online finance and P2P lending. The new business has been a quick success, with revenue from that part of its mix jumping 126% year-on-year to 1.52 billion yuan in the first half of 2022. To diversify its revenue, the group launched an “after-market business” in 2020, which has also been growing steadily. That business brought in 88.8 million yuan in revenue in the first half of the year, up 68% year-on-year.

Market Reaction: Shares of Yixin surged 12.2% in early trade on Tuesday, before giving back some of that to close up 5.1% at HK$1.03 at the midday break. They now trade at the lower end of their 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker

China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.